Antibody-drug Conjugates: Technology Growth Opportunities

Antibody-drug Conjugates: Technology Growth Opportunities

Disruptive Technologies and a Conducive Funding Environment are Fostering Growth

RELEASE DATE
21-Dec-2022
REGION
Global
Research Code: DA71-01-00-00-00
SKU: HC03622-GL-TR_27305
AvailableYesPDF Download

$4,950.00

Special Price $4,455.00 save 10 %

In stock
SKU
HC03622-GL-TR_27305

$4,950.00

$4,455.00save 10 %

DownloadLink
ENQUIRE NOW

Description

Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components. The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications.
This study covers several new technologies for the three ADC components (antibody, linker, and payload) and highlights drugs in clinical trials that display potential. It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development. It also provides an overview of the stakeholder ecosystem, identifying notable mergers, acquisitions, and partnerships. A detailed account of the funding landscape has also been provided. The study also analyzes the growth drivers and restraints influencing the market and identifies the key growth opportunities emerging from the changes in this space for stakeholders and market players to leverage.

Table of Contents

Why Is It Increasingly Difficult to Grow?The Strategic Imperative 8™: Factors Creating Pressure on Growth

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Antibody-drug Conjugate (ADC) Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Research Methodology

Research Context and Scope

Segmentation

Growth Drivers

Growth Restraints

Introduction to ADCs

Clinical Potential of ADCs

ADCs: FDA Approvals

ADC Industry Trends

Incremental Innovations in ADCs

ADC Challenges and Novel Solutions

ADC Challenges and Novel Solutions (continued)

Characteristics of ADC Linkers

Types of Conventional ADC Linkers

Platforms for ADC Linkers

Platforms for ADC Linkers (continued)

Platforms for ADC Linkers (continued)

Platforms for adc Linkers (continued)

ADC Linker Developments

Platforms to Improve adc Conjugation

Platforms to Improve adc Conjugation (continued)

Platforms to Improve adc Conjugation (continued)

Characteristics of a Suitable Antibody for ADCs

Platforms for ADC Antibodies

Platforms for ADC Antibodies (continued)

Antibody Developments for ADC

Characteristics of a Suitable Cytotoxic Payload for an ADC

Platforms for Cytotoxic Payload for an ADC

Platforms for Cytotoxic Payload for an ADC (continued)

Payload Developments for ADCs

Novel Platforms for ADC Delivery

Impact on CDMOs

ADC: Analysis Technologies, Challenges, and New Developments

ADC: Clinical Pipeline

M&As

Partnerships and Collaborations for ADCs

Partnerships and Collaborations for ADCs (continued)

Partnerships and Collaborations for ADCs (continued)

Technology Licensing Deals for ADC Development

Funding Analysis

Funding Analysis (continued)

Funding Analysis (continued)

Growth Opportunity 1: Non-oncological Indications

Growth Opportunity 1: Non-oncological Indications (continued)

Growth Opportunity 2: Manufacturing and Supply Chain

Growth Opportunity 2: Manufacturing and Supply Chain (continued)

Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies

Growth Opportunity 3: Advancements in Linker Chemistry and Antibodies (continued)

Your Next Steps

Why Frost, Why Now?

Legal Disclaimer

Antibody-drug conjugates (ADCs) are therapies that target cancer cells with antigen-specific antibodies and highly toxic payloads. ADCs are currently generating interest among drug developers, contract manufacturing companies, regulatory agencies, and other stakeholders. The rise in the number of drug approvals has also sparked interest in further developing this technology, with several companies developing solutions for one or more ADC components. The development of technologies is ongoing and will only increase as applications of ADCs increasingly expand into non-oncologic indications. This study covers several new technologies for the three ADC components (antibody, linker, and payload) and highlights drugs in clinical trials that display potential. It provides an overview of key technology platforms, patents, analytical techniques, and manufacturing developments, covering the various technological advancements that may see adoption in ADC development. It also provides an overview of the stakeholder ecosystem, identifying notable mergers, acquisitions, and partnerships. A detailed account of the funding landscape has also been provided. The study also analyzes the growth drivers and restraints influencing the market and identifies the key growth opportunities emerging from the changes in this space for stakeholders and market players to leverage.
More Information
Author Lonita lawrence
Industries Healthcare
No Index No
Is Prebook No
Keyword 1 Antibody Drug Conjugate Market
Keyword 2 antibody drug conjugates (ADCs) for cancer therapy
Keyword 3 drug conjugation
Podcast No
WIP Number DA71-01-00-00-00